MacroGenics, Inc.

Day range

$1.93 – $2.21

Open

$2.09

Prev close

$2.25

Volume

1.92M

Market cap

$143.33M

Shares out

63.7M

P/E

—

P/S

0.85

P/B

3.34

P/FCF

—

ROE

-34.2%

ROA

-4.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 23, 2026

  On October 23, 2026, MacroGenics, Inc. issued a press release announcing interim data related to its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumors.

• Director departureJul 8, 2026

  On July 1, 2026, Karen Ferrante, M.D. provided notice to the board of directors (the "Board") of MacroGenics, Inc. (the "Company") of her decision to resign from the Board, effective September 1, 2026. Dr. Ferrante's decision was for personal reasons and was not the result of any disagreement with the Company or any matter relating to the Company's operations, policies or practices.

• Divestiture completionJul 7, 2026

  Effective as of June 30, 2026, MacroGenics, Inc. (the "Company") completed the previously announced sale (the "Closing") of certain assets and liabilities related to its GMP manufacturing operations, including its CDMO business (the "CDMO Operations") conducted by the Company at its manufacturing facility located at 9704 Medical Center Drive, Rockville, Maryland and related warehouse operations located at 4735 Arcadia Drive, Frederick, Maryland to Bora Pharmaceuticals Co., Ltd., a company organized under the laws of Taiwan ("Bora"), and Bora Biologics USA, LLC, a Delaware limited liability company (collectively, the "Purchaser"). The Purchaser paid the Company $122.5 million, before transaction fees and expenses.

• Divestiture agreementMay 12, 2026

  On May 11, 2026, MacroGenics, Inc., a Delaware corporation (the "Company"), entered into an Asset Purchase Agreement (the "Purchase Agreement") with Bora Pharmaceuticals Co., Ltd., a company organized under the laws of Taiwan ("Bora"), and Bora Biologics USA, LLC, a Delaware limited liability company (collectively, the "Purchaser"), pursuant to which the Company agreed to sell to the Purchaser assets and current liabilities related to its GMP manufacturing operations, including its CDMO business (the "CDMO Operations").

• Licensing agreementMay 4, 2026

  In exchange, the parties revised the capped royalty interest payable to Sagard on future global net sales of ZYNYZ, such that all royalty rights under the License Agreement will revert back to the Company once Sagard has received aggregate royalty payments of either 1.70x of the Aggregate Purchase Price by September 30, 2032, or 2.0x of the Aggregate Purchase Price at any time thereafter.

Days to cover

10.9

Short interest

7.04M

Avg volume

645.91K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
  positiveZacks Investment Research· Oct 9, 2026
• Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
  positiveGlobeNewswire Inc.· Sep 8, 2026
• MacroGenics to Participate in Upcoming Investor Conferences
  neutralGlobeNewswire Inc.· Feb 26, 2026
• MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
  negativeGlobeNewswire Inc.· Feb 23, 2026
• [Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
  positiveGlobeNewswire Inc.· Jan 14, 2026